Skip to main content
Vineet Laboratories Limited logo

Vineet Laboratories Limited — Investor Relations & Filings

Ticker · VINEETLAB ISIN · INE505Y01010 LEI · 98450053FEE2D64C6147 BSE.NS Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country IN India
Listing BSE.NS VINEETLAB

About Vineet Laboratories Limited

http://vineetlabs.co.in/

Vineet Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and API intermediates. The company focuses on producing high-quality chemical compounds through advanced research and development, catering to diverse therapeutic segments including anti-retroviral, anti-diabetic, and anti-hypertensive treatments. Its core operations involve the synthesis of complex molecules and fine chemicals, supported by manufacturing facilities that adhere to rigorous quality management systems. Vineet Laboratories provides custom synthesis and contract manufacturing services, positioning itself as a technical partner for global healthcare organizations. The company emphasizes process optimization and cost-effective production to deliver reliable chemical solutions for large-scale pharmaceutical applications.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2024-08-14 English
Financial Result Updates
Regulatory Filings
2024-08-13 English
Outcome of Board Meeting
Regulatory Filings
2024-08-13 English
Board Meeting — VINEET LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 13-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company f…
Regulatory Filings
2024-07-31 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about the scheduled date of a Board Meeting where the company will consider and approve unaudited standalone financial results for the first quarter ended June 30, 2024. It also mentions the closure of the trading window in compliance with SEBI regulations. The document is an announcement of an upcoming event (Board Meeting) and financial results approval, not the financial results report itself. The document length is short (1755 characters) and serves as an intimation rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement under SEBI Listing Obligations and Disclosure Requirements.
2024-07-31 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, certifying that no securities were received for dematerialisation/rematerialisation during the quarter ended 30.06.2024. It is addressed to the Compliance Officer and is a formal attestation letter. The document length is short (1228 characters) and contains no financial data or report content. It is primarily a certification letter related to regulatory compliance rather than a financial report or announcement. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2024-07-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.